EGFR and non-small cell lung carcinoma: In our sample of RCTs, several investigated combination therapies against a control that has the same mechanism of action as the standard-of-care drug (e.g., almonertinib [an EGFR tyrosine kinase inhibitor] for untreated advanced EGFR mutation-positive non-small cell lung cancer [NSCLC]).